Sindbis virus

Sindbis virus

MATERIAL SAFETY DATA SHEET - INFECTIOUS SUBSTANCES

SECTION I - INFECTIOUS AGENT

NAME: Sindbis virus

SYNONYM OR CROSS REFERENCE: Epidemic polyarthritis and rash, Sindbis virus disease, SIN, ockelbo virus

CHARACTERISTICS: Family Togaviridae, genus Alphavirus; enveloped virions icosahedral with 40-70 nm diameter, single-stranded, positive-sense RNA genome

SECTION II - HEALTH HAZARD

PATHOGENICITY: Self-limiting febrile viral disease. Sudden onset of fever, rash, arthralgia or arthritis, lassitude, headache and myalgia; rash may precede or follow joint manifestations by 1-2 days ;exanthem on trunk progressing to face, legs, palm, soles and lasts on average 10 days; signs of jaundice and myocardial damage are reported but rare; often no recognized clinical disease manifestations

EPIDEMIOLOGY: Common in Africa, Asia, Australia, Middle East, Eastern Europe, Scandinavia and the Commonwealth of Independent States

HOST RANGE: Humans, mammals, birds

INFECTIOUS DOSE: Not known

MODE OF TRANSMISSION: By the bite of an infectious mosquito

INCUBATION PERIOD: less than 7 days

COMMUNICABILITY: No evidence of person-to-person transmission documented

SECTION III - DISSEMINATION

RESERVOIR: Birds

ZOONOSIS: Yes - by the bite of an infected mosquito

VECTORS: Mosquitoes (Anopheles, Aedes, Culex and Culista spp.)

SECTION IV - VIABILITY

DRUG SUSCEPTIBILITY: No specific antiviral available to date

SUSCEPTIBILITY TO DISINFECTANTS: Susceptible to 70% ethanol, 1% sodium hypochlorite, 2% glutaraldehyde, organic solvents/detergents

PHYSICAL INACTIVATION: Sensitive to heat, UV and gamma irradiation and freezing

SURVIVAL OUTSIDE HOST: Survives in blood up to 2 days at room temperature

SECTION V - MEDICAL

SURVEILLANCE: Monitor for symptoms; confirm by serological analysis

FIRST AID/TREATMENT: Mainly supportive therapy

IMMUNIZATION: None available

PROPHYLAXIS: None available

SECTION VI - LABORATORY HAZARDS

LABORATORY-ACQUIRED INFECTIONS: None reported to date

SOURCES/SPECIMENS: Blood specimens

PRIMARY HAZARDS: Accidental parenteral inoculation; droplet exposure of the mucous membranes

SPECIAL HAZARDS: None

SECTION VII - RECOMMENDED PRECAUTIONS

CONTAINMENT REQUIREMENTS: Biosafety level 2 practices and containment facilities for all activities involving the virus or infectious or potentially infectious body fluids or tissues

PROTECTIVE CLOTHING: Laboratory coat; gloves when skin contact with infectious materials is unavoidable

OTHER PRECAUTIONS: None

SECTION VIII - HANDLING INFORMATION

SPILLS: Allow aerosols to settle; wearing protective clothing, gently cover the spill with absorbent paper towel and apply 1% sodium hypochlorite, starting at the perimeter and working towards the center; allow sufficient contact time (30 min) before clean up

DISPOSAL: Decontaminate all wastes before disposal; steam sterilization, incineration, chemical disinfection

STORAGE: In sealed containers that are appropriately labelled

SECTION IX - MISCELLANEOUS INFORMATION

Date prepared: March, 2001

Prepared by: Office of Laboratory Security, PHAC

Although the information, opinions and recommendations contained in this Material Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date.

Copyright ©

Health Canada, 2001

This MSDS / PSDS document, provided by Public Health Agency of Canada (PHAC), is offered here as a FREE public service to visitors of MSDSonline. As outlined in this site’s Terms of Use, MSDSonline is not responsible for the accuracy, content or any aspect of the information contained therein.